| Pulmonary arterial hypertension
WINREVAIR vs Orenitram
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Winrevair vs Orenitram with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOrenitram has a higher rate of injection site reactions vs Winrevair based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Orenitram but not Winrevair, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Winrevair
Orenitram
At A Glance
Subcutaneous
Every 3 weeks
Activin signaling inhibitor
Oral
Two to three times daily
Prostacyclin mimetic
Indications
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Pulmonary arterial hypertension Starting dose 0.3 mg/kg subcutaneously every 3 weeks; target dose 0.7 mg/kg subcutaneously every 3 weeks after verifying acceptable hemoglobin and platelet count. Check hemoglobin and platelets before each dose for the first 5 doses or longer if values are unstable.
Pulmonary arterial hypertension Starting dose 0.125 mg TID or 0.25 mg BID with food; titrate by 0.125 mg TID or 0.25-0.5 mg BID no more frequently than every 3-4 days; maximum daily dose 120 mg.
Contraindications
—
- Severe hepatic impairment (Child Pugh Class C)
Adverse Reactions
Most common (>=10%) Headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, erythema, increased hemoglobin
Serious Erythrocytosis, severe thrombocytopenia (platelet count <50,000/mm3), serious bleeding, intrapulmonary right-to-left shunting
Postmarketing Pericardial effusion
Most common (>10%) Headache, diarrhea, nausea, vomiting, jaw pain, flushing
Postmarketing Dizziness, dyspepsia, vomiting, myalgia, arthralgia
Pharmacology
Sotatercept-csrk is an activin signaling inhibitor that binds to activin A and other TGF-beta superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in pulmonary arterial hypertension.
Prostacyclin mimetic; treprostinil causes direct vasodilation of pulmonary and systemic arterial vascular beds, inhibits platelet aggregation, and inhibits smooth muscle cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Winrevair
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (9/12) · Qty limit (9/12)
Orenitram
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Winrevair
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (2/8)
Orenitram
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Winrevair
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Orenitram
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/fillfill
Merck Access Co-pay Assistance: WinrevairCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
WinrevairView full Winrevair profile
OrenitramView full Orenitram profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.